Aditxt Inc is a biotech company focused on enhancing the immune system through innovative technologies designed to promote immune tolerance. The company seeks to develop therapies that can help manage and treat immune-related diseases by leveraging its proprietary platform to create customized solutions. Aditxt's research and development efforts aim to address a range of immunological disorders, potentially transforming the landscape of immunotherapy and improving patient outcomes through better immune system management. Read More
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Stay updated with the latest market activity on Tuesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
Aditxt (NASDAQ: ADTX), a social innovation platform advancing health innovations, announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic (R) Endometriosis Test (MET(TM)), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET’s performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery. The first site, Dedicated to Women OB/GYN in Dover, Del., has begun enrollment. Pearsanta President Chris Mitton said the milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis.
Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has begun enrollment in their prospective clinical study evaluating the Mitomic® Endometriosis Test (MET™), a novel blood-based diagnostic designed to aid in the early detection of endometriosis.
$7.3 Million Fuels Upcoming Launches of Winnie & Friends, Stan Lee Universe , and Bitcoin Brigade as TOON Strengthens Its Global Streaming, Licensing, and Franchise Expansion
The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt”, or the “Company”), a social innovation platform accelerating promising health innovations, today announced an update on its wholly owned subsidiary Adimune, Inc. (“Adimune”), which is pioneering a DNA-based therapeutic platform designed to reprogram the immune system. Adimune’s intellectual property portfolio now includes 96 granted and 22 pending patents that are owned or exclusively licensed by Aditxt, supporting the company’s strategy to address the global autoimmune therapeutics market, which is estimated at over $160 billion by 2030.
